2008 Press Releases

DateTitle 
December 03, 2008POZEN Announces Positive Top Line Results for Its PN 400 Phase 3 TrialsPrinter Friendly Version
December 02, 2008POZEN To Participate in The RBC Capital Markets 2008 Healthcare ConferencePrinter Friendly Version
November 11, 2008POZEN'S PA32520 Study Data Demonstrated Better Upper Gastrointestinal ProtectionPrinter Friendly Version
October 29, 2008POZEN Reports Third Quarter 2008 ResultsPrinter Friendly Version
October 22, 2008POZEN Announces October 29, 2008 Webcast of Third Quarter 2008 ResultsPrinter Friendly Version
October 17, 2008POZEN Confirms ANDA Filing for Treximet(R) TabletsPrinter Friendly Version
October 17, 2008POZEN Informed of FDA Internal Review of Gastric Ulcers as a Primary Endpoint in Clinical TrialsPrinter Friendly Version
September 10, 2008POZEN To Present at The UBS Life Sciences ConferencePrinter Friendly Version
September 08, 2008POZEN Sponsors Habitat for Humanity Home in Hillsborough, North CarolinaPrinter Friendly Version
August 26, 2008POZEN To Present at the 3rd Annual Citi Biotech DayPrinter Friendly Version
August 01, 2008POZEN Receives Initial FDA Response To PA32540 SPAPrinter Friendly Version
July 29, 2008POZEN Reports Second Quarter 2008 ResultsPrinter Friendly Version
July 24, 2008POZEN to Present at the 2008 BMO Capital Markets Focus on Healthcare ConferencePrinter Friendly Version
July 15, 2008POZEN Announces July 29, 2008 Webcast of Second Quarter 2008 ResultsPrinter Friendly Version
June 16, 2008POZEN To Present at the Jefferies 2nd Annual Healthcare ConferencePrinter Friendly Version
June 09, 2008POZEN Demonstrates Bioequivalence to Enteric Coated Aspirin for PA32540Printer Friendly Version
June 02, 2008POZEN To Present at the Seventh Annual Needham & Co., LLC Biotechnology & Medical Technology ConferencePrinter Friendly Version
May 19, 2008POZEN Announces PN 200 Podium Presentation at Digestive Disease WeekPrinter Friendly Version
May 15, 2008POZEN To Present at the Citigroup Global Healthcare ConferencePrinter Friendly Version
May 14, 2008POZEN IND and NDA for Treximet(TM) (Sumatriptan/Naproxen Sodium) Transferred to GlaxoSmithKlinePrinter Friendly Version
May 08, 2008POZEN Reports First Quarter 2008 ResultsPrinter Friendly Version
May 01, 2008POZEN To Present at Baird's 2008 Growth Stock ConferencePrinter Friendly Version
April 28, 2008POZEN Announces Receipt of $20 Million in Milestone Payments from GlaxoSmithKlinePrinter Friendly Version
April 25, 2008POZEN Announces May 8, 2008 Webcast of First Quarter 2008 ResultsPrinter Friendly Version
April 15, 2008Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of MigrainePrinter Friendly Version
March 04, 2008POZEN To Present at the Cowen and Company 28th Annual Healthcare ConferencePrinter Friendly Version
February 26, 2008POZEN Reports Fourth Quarter and Year End 2007 ResultsPrinter Friendly Version
February 21, 2008POZEN's Dr. William Kelce Appointed Adjunct Associate Professor at UNC, Chapel HillPrinter Friendly Version
February 14, 2008POZEN to Present at the Susquehanna Financial Group's Second Annual Significant Options in Healthcare ConferencePrinter Friendly Version
February 12, 2008POZEN Announces February 26, 2008 Webcast of Fourth Quarter and Full Year 2007 ResultsPrinter Friendly Version
January 16, 2008POZEN to Present at the Wachovia Securities 2008 Small & Mid Cap Healthcare ConferencePrinter Friendly Version
January 15, 2008POZEN Submits Human Lymphocyte Study for Treximet(TM) (Formerly Known as Trexima(TM))Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.